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direct costs of the medications were ascertained from the
latest monthly index for medical specialities (MIMS), and
from standard chemists, and pharmaceutical firms. The
statistical mode or most frequent cost was considered for
further computations.
RESULTS: Regarding antidepressants, tricyclics were noted
to have the following annual direct costs (1 US $  Rs. 43):
Imipramine Rs. 1130 (US$26.3), amitriptyline Rs. 1460
($34), dothiepin Rs. 2410 ($56.1), trimipramine Rs. 2430
($56.5) and clomipramine Rs. 6130 ($142.6). Fluoxetine
has an annual cost of Rs. 840 ($19.5), mianserin Rs. 2010
($46.7), amoxapine Rs. 3835 ($89.1), amineptine Rs.
10,700 ($248.8), and the most expensive, tianeptine Rs.
21,000 ($488). The recently introduced antidepressant ser-
traline has an annual cost of Rs. 2740 ($63.7). Prophylaxis
for affective disorders with lithium therapy would have an
annual cost of Rs. 1200 ($27.9). Regarding antipsychotics
the annual direct costs of oral medications of chlorprom-
azine and haloperidol were same, Rs. 2000 ($46.5), long
acting oral penfluridol Rs. 500 ($11.6), and depot long act-
ing injectable fluphenazine decanoate, haloperidol de-
canoate, and flupenthixol Rs. 750 ($17.4), Rs. 1500 ($34.9)
and Rs. 2100 ($48.8), respectively. Newer atypical antipsy-
chotics risperidone, Rs. 4500 ($104.7) and clozapine Rs.
5500 ($127.9). Benzodiazepines have an annual cost of
$7.5 for diazepam, $3.5 for lorazepam and chlordiazep-
oxide, $2.8 for oxazepam, and $17.6 for alprazolam. Sleep
medications nitrazepam, flurazepam, and zopiclone have an
annual cost of $3.3, $8, and $18.8, respectively.
CONCLUSION: The annual direct costs are compara-
tively less than those in Western nations, but nevertheless
these produce a significant burden on the Indian families,
and are a common reason for poor compliance. Another
trend that can be noted above is that newer antidepres-
sants like amineptine and tianeptine, antipsychotics like
risperidone and clozapine, and hypnotics like zopiclone
are much more expensive than the older medications.
Thus, the annual direct costs of medications are only
likely to increase with time, enhancing the financial bur-
den in the treatment of the psychiatric disorders.
PNP18
USE OF ANTIPSYCHOTIC MEDICATIONS AT 
BASELINE IN A PROSPECTIVE STUDY OF THE 
COURSE OF TREATMENT FOR SCHIZOPHRENIA
Johnstone BM1, Mukundan MV1,2, Loosbrock DL1,
Dulisse BK1,3
1Health Outcomes Evaluation Group, United States Medical 
Division, Eli Lilly and Company, Indianapolis, IN, USA; 
2Department of Economics, Indiana University at Indianapolis, 
Indianapolis, IN, USA; 3Statistical and Mathematical Sciences, 
Lilly Research Laboratories, Eli Lilly and Company, 
Indianapolis, IN, USA
OBJECTIVES: To profile utilization of antipsychotic
medications at baseline in a prospective study of the out-
comes of treatment for schizophrenia in large systems of
care, and to evaluate characteristics associated with the
receipt of antipsychotic medication and the type of medi-
cation prescribed.
METHODS: Data are obtained from the Schizophrenia
Care and Assessment Program, a prospective study of the
course and outcomes of treatment for schizophrenia in six
large systems of care in the United States. The analysis
sample consists of approximately 1100 patients. Antipsy-
chotic medication use at baseline in this sample is profiled.
The effect of patient characteristics and prior period (pre-
vious 6 months) service utilization and medication history
on receipt of antipsychotic medication therapy at baseline
and the type of medication prescribed is modeled using lo-
gistic regression.
RESULTS: The presentation will profile antipsychotic
utilization at baseline in this sample of patients receiving
care in large service systems, and characterize the distri-
bution of use of conventional, new generation, and depot
medication. Regression analysis will evaluate factors as-
sociated with the receipt of antipsychotic medication
therapy and type of medication prescribed. Predictors
will include: patient demographic status (age, gender,
race/ethnicity, education, marital status, income, health
insurance status), diagnosis (type of schizophrenia), psy-
chiatric history, and pre-period health services utilization
and medication history.
CONCLUSIONS: The introduction of new pharmaco-
logic treatments for schizophrenia and the development of
evidence-based standards of care has accelerated the need
for information on patterns of medication therapy and
outcomes in usual care settings. This presentation will
profile antipsychotic medication use and factors associ-
ated with current prescribing practices in a large sample
of patients with schizophrenia who receive care in large
service systems.
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With the growing elderly population, the number of
older patients with mental and behavioral disorders has
increased. Psychotropic drugs are an integral part of
treatment for these conditions.
OBJECTIVE: This study describes the psychotropic agent
prescribing for the elderly in clinic settings during 1996.
METHODS: Data were abstracted from the 1996 Na-
tional Ambulatory Medical Care Survey and the Na-
tional Hospital Ambulatory Medical Care Survey. All
visits of patients 65 years of age or older involving psy-
chotropic drugs were selected from the national surveys.
National visit estimates and visit rates were derived based
on the patient sampling weight to describe psychotropic
prescribing for the elderly in ambulatory clinics.
RESULTS: Psychotropic medications were prescribed in
an estimated 16.55 million ambulatory clinic visits for
